A pharmacokinetic (PK) pharmacodynamic (PD) driven first-in-human study of the oral class I PI3K inhibitor CH5132799, in patients with advanced solid tumors.

Aurelius Omlin, Sarah P. Blagden, Monsterrat Blanco et al.|Journal of Clinical Oncology|2012

Cited by 5